CN1510052A - Tumour necrosis factor antibody preparing method and medicinal composition thereof - Google Patents
Tumour necrosis factor antibody preparing method and medicinal composition thereof Download PDFInfo
- Publication number
- CN1510052A CN1510052A CNA021576599A CN02157659A CN1510052A CN 1510052 A CN1510052 A CN 1510052A CN A021576599 A CNA021576599 A CN A021576599A CN 02157659 A CN02157659 A CN 02157659A CN 1510052 A CN1510052 A CN 1510052A
- Authority
- CN
- China
- Prior art keywords
- ser
- gly
- antibody
- seq
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title abstract description 32
- 239000000203 mixture Substances 0.000 title abstract description 3
- 102000018594 Tumour necrosis factor Human genes 0.000 title description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 title description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- 108020004414 DNA Proteins 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 28
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 24
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 29
- 239000012634 fragment Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical group C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 5
- 241000699802 Cricetulus griseus Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 102000057041 human TNF Human genes 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 102220023258 rs387907548 Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102220023257 rs387907546 Human genes 0.000 description 3
- 102220023256 rs387907547 Human genes 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 102220369446 c.1274G>A Human genes 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000019587 texture Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Cell strain | 2B3 | ?3D9 | ?4C4 | ?5H3 | ?7A3 | ?4B5 | ?5A4 | ?6F5 |
Expression amount | 255.7 | ?174.9 | ?242.8 | ?144.7 | ?262.3 | ?177.2 | ?253.4 | ?290.7 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02157659 CN1225479C (en) | 2002-12-23 | 2002-12-23 | Tumour necrosis factor antibody preparing method and medicinal composition thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02157659 CN1225479C (en) | 2002-12-23 | 2002-12-23 | Tumour necrosis factor antibody preparing method and medicinal composition thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1510052A true CN1510052A (en) | 2004-07-07 |
CN1225479C CN1225479C (en) | 2005-11-02 |
Family
ID=34236628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02157659 Expired - Lifetime CN1225479C (en) | 2002-12-23 | 2002-12-23 | Tumour necrosis factor antibody preparing method and medicinal composition thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1225479C (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101111521B (en) * | 2004-12-29 | 2011-08-24 | 株式会社柳韩洋行 | Humanized antibody specific for tumor necrosis factor-alpha |
CN102229655B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide resistant to rheumatoid arthritis and application of polypeptide in pharmacy |
CN102229656B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide against rheumatoid arthritis and application thereof in pharmacy |
CN102229658B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Anti-rheumatoid arthritis polypeptide and its application in pharmacy |
CN102229654B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide resistant to rheumatoid arthritis and application of polypeptide in pharmacy |
CN102229657B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide against rheumatoid arthritis and application thereof in pharmacy |
CN102229653B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide resistant to rheumatoid arthritis and application of polypeptide in pharmacy |
WO2012116595A1 (en) * | 2011-02-28 | 2012-09-07 | 珠海市丽珠单抗生物技术有限公司 | Tumor necrosis factor-α humanized antibody |
CN103336129A (en) * | 2005-11-01 | 2013-10-02 | 阿布维生物技术有限公司 | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
US8658171B2 (en) | 2011-02-28 | 2014-02-25 | Livzon Mabpharm Inc. | Humanized anti-TNFα antibodies |
CN111153994A (en) * | 2019-12-31 | 2020-05-15 | 武汉班科生物技术股份有限公司 | Human monoclonal antibodies to human tumor necrosis factor |
-
2002
- 2002-12-23 CN CN 02157659 patent/CN1225479C/en not_active Expired - Lifetime
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101111521B (en) * | 2004-12-29 | 2011-08-24 | 株式会社柳韩洋行 | Humanized antibody specific for tumor necrosis factor-alpha |
CN103336129A (en) * | 2005-11-01 | 2013-10-02 | 阿布维生物技术有限公司 | Methods and compositions for diagnosing ankylosing spondylitis using biomarkers |
CN102229655B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide resistant to rheumatoid arthritis and application of polypeptide in pharmacy |
CN102229656B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide against rheumatoid arthritis and application thereof in pharmacy |
CN102229658B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Anti-rheumatoid arthritis polypeptide and its application in pharmacy |
CN102229654B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide resistant to rheumatoid arthritis and application of polypeptide in pharmacy |
CN102229657B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide against rheumatoid arthritis and application thereof in pharmacy |
CN102229653B (en) * | 2009-10-23 | 2012-05-23 | 山东省医药生物技术研究中心 | Polypeptide resistant to rheumatoid arthritis and application of polypeptide in pharmacy |
WO2012116595A1 (en) * | 2011-02-28 | 2012-09-07 | 珠海市丽珠单抗生物技术有限公司 | Tumor necrosis factor-α humanized antibody |
US8658171B2 (en) | 2011-02-28 | 2014-02-25 | Livzon Mabpharm Inc. | Humanized anti-TNFα antibodies |
CN111153994A (en) * | 2019-12-31 | 2020-05-15 | 武汉班科生物技术股份有限公司 | Human monoclonal antibodies to human tumor necrosis factor |
CN111153994B (en) * | 2019-12-31 | 2021-10-15 | 武汉班科生物技术股份有限公司 | Human monoclonal antibodies to human tumor necrosis factor |
Also Published As
Publication number | Publication date |
---|---|
CN1225479C (en) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1187374C (en) | Humanized antibody specific for human 4-1BB and pharmaceutical compsn comprising same | |
CN1263507C (en) | APRIL receptor (BCMA) and uses thereof | |
CN1317303C (en) | Anti-human tenascin monoclonal antibody | |
CN1604966A (en) | Direct targeting binding proteins | |
CN1214115C (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug | |
CN1422333A (en) | Polypeptide inducing apoptosis | |
CN1599867A (en) | Immunocytokines with modulated selectivity | |
CN1076966A (en) | The clone of the humanized monoclonal antibodies of anti-human interleukin-4 and expression | |
CN1277632A (en) | Natural human antibody | |
CN101074261A (en) | TRAIL receptor I and/or TRAIL receptor 2 specific antibody and its use | |
CN1087681A (en) | New antibodies with passive immunity of pathogenic bacterial infection in the anti-human body | |
CN101035809A (en) | Humanized anti-tag-72 monoclonal antibodies | |
CN1273588A (en) | Amino acid sequences for therapeutical and prophylacticapplications to disedses due to i (clostridium difficile) toxinc | |
CN1809592A (en) | Recombinant antibodies and fragments recognising ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumours | |
CN1839157A (en) | Antibodies against interleukin-22 and uses therefor | |
CN1225479C (en) | Tumour necrosis factor antibody preparing method and medicinal composition thereof | |
CN1263556A (en) | Anti-GPIIB/IIIA recombinant antibodies | |
CN101037671A (en) | Hybridoma cell line and anti-human erythrocyte surface H antigen monoclonal antibodies generated thereof | |
CN1283662C (en) | Antagonistic anti-hFAS ligand human antibodies and fragments thereof | |
CN1210307C (en) | Humanized anti-CD 20 monoclonal antibody | |
CN1156460A (en) | Reconstructed hyman antibody against human interleukin-8 | |
CN1566341A (en) | In vitro molecular directed evolution method for reshaping antibody | |
CN1210308C (en) | Humanized anti-HER 2 monoclonal antibody, its preparation method and pharmaceutical composition thereof | |
CN1225480C (en) | Anti CD52 monoclonal antibody, coding sequence and use thereof | |
CN1310758A (en) | Novel method for isolating gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI BAISHIDA BIOLOGICAL TECHNOLOGICAL CO.,LTD Free format text: FORMER OWNER: MA JING Effective date: 20090904 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090904 Address after: Jing Shanghai Road, Zhangjiang Park No. 351 Building No. 1 room 431 Patentee after: Shanghai Sinolink Biological Technology Co.,Ltd. Address before: Shanghai Zhangjiang road 351 GuoShouJing 1 Building No. 440 room Patentee before: Ma Jing |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161229 Address after: 201203 Shanghai, China (Shanghai) free trade zone, No. 99 Road, building No. 3, room No. 301 Patentee after: SHANGHAI MAITAI JUNAO BIOTECHNOLOGY CO.,LTD. Address before: 201203 Shanghai Guo Shou Jing Road, Zhangjiang Park No. 351 Building No. 1 room 431 Patentee before: Shanghai Sinolink Biological Technology Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20051102 |
|
CX01 | Expiry of patent term |